Journal of Clinical Endocrinology & Metabolism, Vol 81, 84-92, Copyright © 1996 by Endocrine Society

ARTICLES

Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men--a clinical research center study

HB Baum, BM Biller, L Katznelson, DS Oppenheim, DR Clemmons, KB Cannistraro, DA Schoenfeld, SA Best and A Klibanski
Department of Medicine, Massachusetts General Hospital, Boston 02114, USA.

It is not known how patients who acquire GH deficiency (GHD) in adulthood differ in measures of GH secretion from normal adults. To characterize measures of GH secretion in such patients compared to those in normal subjects, we studied 23 men (median age, 51 yr; range, 32-62 yr) with adult-onset pituitary disease, defined as GH-deficient based on having no detectable GH response to two pharmacological agents, and 17 normal men. Patients less than 50 yr old received insulin (0.1 U/kg, i.v.) and clonidine (0.15 mg, orally), whereas those 50 yr of age or older as well as normal controls received arginine (30 g, i.v.) and clonidine. Patients were compared to normal men by investigating GH sampling every 10 min for 24 h and serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein 2 (IGFBP-2), IGFBP-3, and GH-binding protein. Frequent venous sampling of GH was analyzed in terms of mean 24-h levels, pooled 24-h GH, mean levels over the 12 h between 2000-0800 h (mean overnight GH level), and pulse analysis (pulses per 24 h and pulse amplitude) by the Pulsar computer program. Although there were significant differences between the two groups for almost all measures of GH secretion, overlap between the groups was always present. GH levels measured using a highly sensitive chemiluminescence assay on 24-h pools derived from frequent sampling displayed the least overlap between the two groups, as only 2 of 17 normal controls overlapped with the GHD patients. The pooled 24-h GH level using this technique was significantly lower in patients with GHD than in controls (0.117 +/- 0.021 vs. 0.861 +/- 0.098 micrograms/L; P < 0.0001). In the analysis of frequent GH sampling using a standard immunoradiometric assay, mean overnight GH levels provided the best separation between the two groups, as all 23 patients had values of 0.6 microgram/L or less, and 13 of 17 normal controls had values greater than 0.6 microgram/L. The mean overnight GH level in patients was 0.6 +/- 0.0 microgram/L compared to 1.0 +/- 0.1 microgram/L in controls (P < 0.0001). The mean 24-h GH level in patients was 0.5 +/- 0.0 microgram/L compared to 0.8 +/- 0.1 microgram/L in normal controls (P < 0.0001). GH pulse frequency and pulse amplitude were also reduced in patients with GHD compared to those in normal controls [1.7 +/- 0.5 vs. 5.1 +/- 0.5 pulses/24 h (P < 0.0001) and 0.6 +/- 0.1 vs. 2.8 +/- 0.4 microgram/L (P < 0.0001), respectively]. The mean serum IGF-I level was significantly lower in patients with GHD than in normal controls (106.7 +/- 8.0 vs. 218.7 +/- 16.7 microgram/L; P < 0.0001). Three of 23 patients overlapped with control values. Mean serum levels of IGFBP-3 and the serum IGF-I/IGFBP-2 ratio were also significantly lower in patients than in controls, but values overlapped substantially. We conclude that overlap occurs on measures of GH secretion between normal men and men identified as GH deficient despite a stringent definition of GHD. The best separation was obtained using pooled 24-h GH levels determined by a highly sensitive chemiluminescence assay.

This article has been cited by other articles:

				K. H. Darzy, R. D. Murray, H. K. Gleeson, S. S. Pezzoli, M. O. Thorner, and S. M. Shalet The Impact of Short-Term Fasting on the Dynamics of 24-Hour Growth Hormone (GH) Secretion in Patients with Severe Radiation-Induced GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 987 - 994. [Abstract] [Full Text] [PDF]

				K. H. Darzy, S. S. Pezzoli, M. O. Thorner, and S. M. Shalet The Dynamics of Growth Hormone (GH) Secretion in Adult Cancer Survivors with Severe GH Deficiency Acquired after Brain Irradiation in Childhood for Nonpituitary Brain Tumors: Evidence for Preserved Pulsatility and Diurnal Variation with Increased Secretory Disorderliness J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2794 - 2803. [Abstract] [Full Text] [PDF]

				M. Maghnie, G. Aimaretti, S. Bellone, G. Bona, J. Bellone, R. Baldelli, C. de Sanctis, L. Gargantini, R. Gastaldi, L. Ghizzoni, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement Eur. J. Endocrinol., April 1, 2005; 152(4): 589 - 596. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Growth Hormone (GH) Responses to GH-Releasing Hormone-Arginine Testing in Human Immunodeficiency Virus Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 32 - 38. [Abstract] [Full Text] [PDF]

				B. M. K. Biller, M. H. Samuels, A. Zagar, D. M. Cook, B. M. Arafah, V. Bonert, S. Stavrou, D. L. Kleinberg, J. J. Chipman, and M. L. Hartman Sensitivity and Specificity of Six Tests for the Diagnosis of Adult GH Deficiency J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2067 - 2079. [Abstract] [Full Text] [PDF]

				M. L. Hartman, B. J. Crowe, B. M. K. Biller, K. K. Y. Ho, D. R. Clemmons, and J. J. Chipman Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 477 - 485. [Abstract] [Full Text] [PDF]

				S. A. Lieberman, A. L. Oberoi, C. R. Gilkison, B. E. Masel, and R. J. Urban Prevalence of Neuroendocrine Dysfunction in Patients Recovering from Traumatic Brain Injury J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2752 - 2756. [Abstract] [Full Text] [PDF]

				M. Maghnie, B. Salati, S. Bianchi, M. Rallo, C. Tinelli, M. Autelli, G. Aimaretti, and E. Ghigo Relationship between the Morphological Evaluation of the Pituitary and the Growth Hormone (GH) Response to GH-Releasing Hormone Plus Arginine in Children and Adults with Congenital Hypopituitarism J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1574 - 1579. [Abstract] [Full Text]

				P. Rietschel, C. Hadigan, C. Corcoran, T. Stanley, G. Neubauer, J. Gertner, and S. Grinspoon Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 504 - 510. [Abstract] [Full Text]

				M. Gasperi, G. Aimaretti, G. Scarcello, G. Corneli, C. Cosci, E. Arvat, E. Martino, and E. Ghigo Low Dose Hexarelin and Growth Hormone (GH)-Releasing Hormone as a Diagnostic Tool for the Diagnosis of GH Deficiency in Adults: Comparison with Insulin-Induced Hypoglycemia Test J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2633 - 2637. [Abstract] [Full Text]

				S. Grinspoon, C. Corcoran, T. Stanley, L. Katznelson, and A. Klibanski Effects of Androgen Administration on the Growth Hormone-Insulin-Like Growth Factor I Axis in Men with Acquired Immunodeficiency Syndrome Wasting J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4251 - 4256. [Abstract] [Full Text]

				F. Cordido, T. Fernandez, T. Martinez, A. Peñalva, R. Peinó, F. F. Casanueva, and C. Dieguez Effect of Acute Pharmacological Reduction of Plasma Free Fatty Acids on Growth Hormone (GH) Releasing Hormone-Induced GH Secretion in Obese Adults with and without Hypopituitarism J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4350 - 4354. [Abstract] [Full Text]

				H. B. A. Baum, L. Katznelson, J. C. Sherman, B. M. K. Biller, D. L. Hayden, D. A. Schoenfeld, K. E. Cannistraro, and A. Klibanski Effects of Physiological Growth Hormone (GH) Therapy on Cognition and Quality of Life in Patients with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3184 - 3189. [Abstract] [Full Text]

				M. S. Gill, A. A. Toogood, P. A. O’Neill, M. O. Thorner, S. M. Shalet, and P. E. Clayton Urinary Growth Hormone (GH), Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Protein-3 Measurements in the Diagnosis of Adult GH Deficiency J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2562 - 2565. [Abstract] [Full Text]

				E. S. Kurland, F. K. W. Chan, C. J. Rosen, and J. P. Bilezikian Normal Growth Hormone Secretory Reserve in Men with Idiopathic Osteoporosis and Reduced Circulating Levels of Insulin-Like Growth Factor-I J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2576 - 2579. [Abstract] [Full Text]

				G. Aimaretti, G. Corneli, P. Razzore, S. Bellone, C. Baffoni, E. Arvat, F. Camanni, and E. Ghigo Comparison between Insulin-Induced Hypoglycemia and Growth Hormone (GH)-Releasing Hormone + Arginine as Provocative Tests for the Diagnosis of GH Deficiency in Adults J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1615 - 1618. [Abstract] [Full Text]

				P. Lucidi, M. Lauteri, S. Laureti, R. Celleno, S. Santoni, E. Volpi, G. Angeletti, F. Santeusanio, and P. De Feo A Dose-Response Study of Growth Hormone (GH) Replacement on Whole Body Protein and Lipid Kinetics in GH-Deficient Adults J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 353 - 357. [Abstract] [Full Text]

				A. A. Toogood, R. M. Nass, S. S. Pezzoli, P. A. O'Neill, M. O. Thorner, and S. M. Shalet Preservation of Growth Hormone Pulsatility Despite Pituitary Pathology, Surgery, and Irradiation J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2215 - 2221. [Abstract] [Full Text] [PDF]

				C. A. Benbassat, K. C. Maki, and T. G. Unterman Circulating Levels of Insulin-Like Growth Factor (IGF) Binding Protein-1 and -3 in Aging Men: Relationships to Insulin, Glucose, IGF, and Dehydroepiandrosterone Sulfate Levels and Anthropometric Measures J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1484 - 1491. [Abstract] [Full Text] [PDF]

				A. Juul, K. W. Kastrup, S. A. Pedersen, and N. E. Skakkebak Growth Hormone (GH) Provocative Retesting of 108 Young Adults with Childhood-Onset GH Deficiency and the Diagnostic Value of Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1195 - 1201. [Abstract] [Full Text] [PDF]